Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 94
Filtrar
1.
Int J Biol Sci ; 20(11): 4114-4127, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39247831

RESUMEN

Osteosarcoma is the most prevalent form of primary malignant bone tumor, primarily affecting children and adolescents. The nerve growth factors (NGF) referred to as neurotrophins have been associated with cancer-induced bone pain; however, the role of NGF in osteosarcoma has yet to be elucidated. In osteosarcoma samples from the Genomic Data Commons data portal, we detected higher levels of NGF and M2 macrophage markers, but not M1 macrophage markers. In cellular experiments, NGF-stimulated osteosarcoma conditional medium was shown to facilitate macrophage polarization from the M0 to the M2 phenotype. NGF also enhanced VCAM-1-dependent monocyte adhesion within the osteosarcoma microenvironment by down-regulating miR-513c-5p levels through the FAK and c-Src cascades. In in vivo xenograft models, the overexpression of NGF was shown to enhance tumor growth, while the oral administration of the TrK inhibitor larotrectinib markedly antagonized NGF-promoted M2 macrophage expression and tumor progression. These results suggest that larotrectinib could potentially be used as a therapeutic agent aimed at mitigating NGF-mediated osteosarcoma progression.


Asunto(s)
Monocitos , Factor de Crecimiento Nervioso , Osteosarcoma , Microambiente Tumoral , Molécula 1 de Adhesión Celular Vascular , Osteosarcoma/metabolismo , Osteosarcoma/tratamiento farmacológico , Osteosarcoma/patología , Humanos , Factor de Crecimiento Nervioso/metabolismo , Animales , Microambiente Tumoral/efectos de los fármacos , Monocitos/metabolismo , Monocitos/efectos de los fármacos , Molécula 1 de Adhesión Celular Vascular/metabolismo , Ratones , Adhesión Celular/efectos de los fármacos , Línea Celular Tumoral , Neoplasias Óseas/metabolismo , Neoplasias Óseas/tratamiento farmacológico , Neoplasias Óseas/patología , Macrófagos/metabolismo , Pirimidinas/farmacología , Pirimidinas/uso terapéutico , Pirazoles/farmacología , Pirazoles/uso terapéutico , Ratones Desnudos
2.
Eur J Gastroenterol Hepatol ; 36(9): 1113-1118, 2024 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-38973530

RESUMEN

BACKGROUND: The efficacy of different nucleos(t)ide analogs in the treatment of chronic hepatitis B virus (CHB) with severe acute exacerbation (SAE) remained unclear. Thus, this study aimed to compare the short-term efficacy of tenofovir disoproxil fumarate (TDF) and entecavir (ETV) in patients having CHB with SAE. METHODS: We analyzed consecutive patients with treatment-naive CHB receiving TDF (n = 36) or ETV (n = 65) for SAE. The primary endpoint was overall mortality or receipt of liver transplantation (LT) by 24 weeks. The secondary endpoints are the comparison of ETV vs. TDF influences on renal function and virological and biochemical responses at 4, 12, 24, and 48 weeks. RESULTS: The baseline characteristics were comparable between the two groups. By 24 weeks, 8 (22%) patients in the TDF group and 10 (15%) patients in the ETV group had either died (n = 15) or received LT (n = 3) ( P  = 0.367). Cox-regression multivariate analysis revealed age ( P  = 0.003), baseline international normalized ratio of prothrombin time ( P  = 0.024), and early presence of hepatic encephalopathy ( P  = 0.003) as independent factors associated with mortality or LT. The two groups of patients achieved comparable biochemical and virological responses at 48 weeks. No significant difference was found in the estimated glomerular filtration rate (eGFR) between the TDF and the ETV groups. However, a significant reduction in the eGFR at 48 weeks, as compared with the baseline, was found in each group. CONCLUSION: TDF and ETV achieved similar short-term clinical outcomes and treatment responses in CHB patients with SAE.


Asunto(s)
Antivirales , Guanina , Hepatitis B Crónica , Tenofovir , Humanos , Guanina/análogos & derivados , Guanina/uso terapéutico , Guanina/efectos adversos , Femenino , Masculino , Hepatitis B Crónica/tratamiento farmacológico , Hepatitis B Crónica/complicaciones , Hepatitis B Crónica/mortalidad , Tenofovir/uso terapéutico , Antivirales/uso terapéutico , Antivirales/efectos adversos , Persona de Mediana Edad , Adulto , Resultado del Tratamiento , Trasplante de Hígado , Estudios Retrospectivos , Progresión de la Enfermedad , Índice de Severidad de la Enfermedad , Tasa de Filtración Glomerular/efectos de los fármacos , ADN Viral/sangre , Carga Viral , Factores de Tiempo , Virus de la Hepatitis B/efectos de los fármacos , Virus de la Hepatitis B/genética , Modelos de Riesgos Proporcionales
3.
J Cell Physiol ; 2024 Jun 28.
Artículo en Inglés | MEDLINE | ID: mdl-38940190

RESUMEN

Chondrosarcoma is a malignant bone tumor that emerges from abnormalities in cartilaginous tissue and is related with lung metastases. Nicotinamide phosphoribosyltransferase (NAMPT) is an adipocytokine reported to enhance tumor metastasis. Our results from clinical samples and the Gene Expression Omnibus data set reveal that NAMPT levels are markedly higher in chondrosarcoma patients than in normal individuals. NAMPT stimulation significantly increased lysyl oxidase (LOX) production in chondrosarcoma cells. Additionally, NAMPT increased LOX-dependent cell migration and invasion in chondrosarcoma by suppressing miR-26b-5p generation through the c-Src and Akt signaling pathways. Overexpression of NAMPT promoted chondrosarcoma metastasis to the lung in vivo. Furthermore, knockdown of LOX counteracted NAMPT-facilitated metastasis. Thus, the NAMPT/LOX axis presents a novel target for treating the metastasis of chondrosarcoma.

4.
Cell Death Dis ; 15(5): 381, 2024 May 30.
Artículo en Inglés | MEDLINE | ID: mdl-38816365

RESUMEN

Osteosarcoma (OS) therapy presents numerous challenges, due largely to a low survival rate following metastasis onset. Nerve growth factor (NGF) has been implicated in the metastasis and progression of various cancers; however, the mechanism by which NGF promotes metastasis in osteosarcoma has yet to be elucidated. This study investigated the influence of NGF on the migration and metastasis of osteosarcoma patients (88 cases) as well as the underlying molecular mechanisms, based on RNA-sequencing and gene expression data from a public database (TARGET-OS). In osteosarcoma patients, the expression of NGF was significantly higher than that of other growth factors. This observation was confirmed in bone tissue arrays from 91 osteosarcoma patients, in which the expression levels of NGF and matrix metallopeptidase-2 (MMP-2) protein were significantly higher than in normal bone, and strongly correlated with tumor stage. In summary, NGF is positively correlated with MMP-2 in human osteosarcoma tissue and NGF promotes osteosarcoma cell metastasis by upregulating MMP-2 expression. In cellular experiments using human osteosarcoma cells (143B and MG63), NGF upregulated MMP-2 expression and promoted wound healing, cell migration, and cell invasion. Pre-treatment with MEK and ERK inhibitors or siRNA attenuated the effects of NGF on cell migration and invasion. Stimulation with NGF was shown to promote phosphorylation along the MEK/ERK signaling pathway and decrease the expression of microRNA-92a-1-5p (miR-92a-1-5p). In in vivo experiments involving an orthotopic mouse model, the overexpression of NGF enhanced the effects of NGF on lung metastasis. Note that larotrectinib (a tropomyosin kinase receptor) strongly inhibited the effect of NGF on lung metastasis. In conclusion, it appears that NGF promotes MMP-2-dependent cell migration by inhibiting the effects of miR-92a-1-5p via the MEK/ERK signaling cascade. Larotrectinib emerged as a potential drug for the treatment of NGF-mediated metastasis in osteosarcoma.


Asunto(s)
Neoplasias Óseas , Movimiento Celular , Metaloproteinasa 2 de la Matriz , Factor de Crecimiento Nervioso , Osteosarcoma , Pirazoles , Pirimidinas , Humanos , Osteosarcoma/tratamiento farmacológico , Osteosarcoma/patología , Osteosarcoma/metabolismo , Osteosarcoma/genética , Factor de Crecimiento Nervioso/metabolismo , Animales , Pirimidinas/farmacología , Pirimidinas/uso terapéutico , Línea Celular Tumoral , Movimiento Celular/efectos de los fármacos , Pirazoles/farmacología , Pirazoles/uso terapéutico , Ratones , Metaloproteinasa 2 de la Matriz/metabolismo , Metaloproteinasa 2 de la Matriz/genética , Neoplasias Óseas/metabolismo , Neoplasias Óseas/tratamiento farmacológico , Neoplasias Óseas/patología , Neoplasias Óseas/genética , Ratones Desnudos , Masculino , Metástasis de la Neoplasia , Femenino , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Ratones Endogámicos BALB C
5.
Int J Mol Sci ; 25(10)2024 May 09.
Artículo en Inglés | MEDLINE | ID: mdl-38791180

RESUMEN

Chondrosarcoma is a malignant bone tumor that arises from abnormalities in cartilaginous tissue and is associated with lung metastases. Lymphangiogenesis plays an essential role in cancer metastasis. Visfatin is an adipokine reported to enhance tumor metastasis, but its relationship with VEGF-D generation and lymphangiogenesis in chondrosarcoma remains undetermined. Our results from clinical samples reveal that VEGF-D levels are markedly higher in chondrosarcoma patients than in normal individuals. Visfatin stimulation promotes VEGF-D-dependent lymphatic endothelial cell lymphangiogenesis. We also found that visfatin induces VEGF-D production by activating HIF-1α and reducing miR-2277-3p generation through the Raf/MEK/ERK signaling cascade. Importantly, visfatin controls chondrosarcoma-related lymphangiogenesis in vivo. Therefore, visfatin is a promising target in the treatment of chondrosarcoma lymphangiogenesis.


Asunto(s)
Neoplasias Óseas , Condrosarcoma , Subunidad alfa del Factor 1 Inducible por Hipoxia , Linfangiogénesis , MicroARNs , Nicotinamida Fosforribosiltransferasa , Factor D de Crecimiento Endotelial Vascular , Humanos , Condrosarcoma/metabolismo , Condrosarcoma/genética , Condrosarcoma/patología , Linfangiogénesis/genética , MicroARNs/genética , MicroARNs/metabolismo , Nicotinamida Fosforribosiltransferasa/metabolismo , Nicotinamida Fosforribosiltransferasa/genética , Subunidad alfa del Factor 1 Inducible por Hipoxia/metabolismo , Subunidad alfa del Factor 1 Inducible por Hipoxia/genética , Factor D de Crecimiento Endotelial Vascular/metabolismo , Factor D de Crecimiento Endotelial Vascular/genética , Neoplasias Óseas/metabolismo , Neoplasias Óseas/patología , Neoplasias Óseas/genética , Animales , Regulación Neoplásica de la Expresión Génica , Línea Celular Tumoral , Ratones , Citocinas/metabolismo , Masculino , Femenino , Sistema de Señalización de MAP Quinasas
6.
Int Immunopharmacol ; 132: 112016, 2024 May 10.
Artículo en Inglés | MEDLINE | ID: mdl-38593506

RESUMEN

Osteoarthritis (OA) is a low-grade inflammatory joint illness in which monocytes migrate and infiltrate synovial tissue, differentiating into the pro-inflammatory M1 macrophage phenotype. IL-17 is a proinflammatory mediator principally generated by Th17 cells, which is elevated in OA patients; nevertheless, investigators have yet to elucidate the function of IL-17 in M1 polarization during OA development. Our analysis of clinical tissues and results from the open online dataset discovered that the level of M1 macrophage markers is elevated in human OA tissue samples than in normal tissue. High-throughput screening demonstrated that MCP-1 is a potential candidate factor after IL-17 treatment in OA synovial fibroblasts (OASFs). Immunohistochemistry data revealed that the level of MCP-1 is higher in humans and mice with OA than in normal tissues. IL-17 stimulation facilitates MCP-1-dependent macrophage polarization to the M1 phenotype. It also appears that IL-17 enhances MCP-1 synthesis in human OASFs, enhancing monocyte migration via the JAK and STAT3 signaling cascades. Our findings indicate the IL-17/MCP-1 axis as a novel strategy for the remedy of OA.


Asunto(s)
Movimiento Celular , Quimiocina CCL2 , Interleucina-17 , Macrófagos , Monocitos , Osteoartritis , Animales , Humanos , Masculino , Ratones , Movimiento Celular/efectos de los fármacos , Células Cultivadas , Quimiocina CCL2/metabolismo , Fibroblastos/efectos de los fármacos , Fibroblastos/inmunología , Interleucina-17/metabolismo , Macrófagos/inmunología , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Ratones Endogámicos C57BL , Monocitos/inmunología , Monocitos/efectos de los fármacos , Monocitos/metabolismo , Osteoartritis/inmunología , Transducción de Señal , Factor de Transcripción STAT3/metabolismo , Membrana Sinovial/inmunología , Membrana Sinovial/patología
7.
Environ Toxicol ; 39(7): 3790-3798, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38497692

RESUMEN

Chondrosarcoma is a malignant bone tumor that arises from abnormalities in cartilaginous tissue and is associated with lung metastases. Extracellular vesicles called exosomes are primarily used as mediators of intercellular signal transmission to control tumor metastasis. Visfatin is an adipokine reported to enhance tumor metastasis, but its relationship with exosome generation in chondrosarcoma motility remains undetermined. Our results found that overexpressing visfatin augments the production of exosomes from chondrosarcoma cells. Visfatin-treated chondrosarcoma exosomes educate macrophage polarization towards the M2 but not M1 phenotype. Interestingly, M2 macrophages polarized by exosomes return to chondrosarcoma cells to facilitate cell motility. According to these findings, chondrosarcoma cells emit more exosomes when treated with visfatin. The stimulation of exosome generation by visfatin polarizes M2 macrophages and enhances the motility of chondrosarcoma.


Asunto(s)
Movimiento Celular , Condrosarcoma , Exosomas , Macrófagos , Nicotinamida Fosforribosiltransferasa , Condrosarcoma/patología , Condrosarcoma/metabolismo , Exosomas/metabolismo , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Humanos , Nicotinamida Fosforribosiltransferasa/metabolismo , Movimiento Celular/efectos de los fármacos , Línea Celular Tumoral , Neoplasias Óseas/patología , Neoplasias Óseas/metabolismo , Citocinas/metabolismo
8.
Int Immunopharmacol ; 130: 111733, 2024 Mar 30.
Artículo en Inglés | MEDLINE | ID: mdl-38387191

RESUMEN

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disorder in which monocytes adhering to synovial tissue differentiate into the pro-inflammatory M1 macrophage phenotype. Nerve growth factors (NGF) referred to as neurotrophins have been associated with inflammatory events; however, researchers have yet to elucidate the role of NGF in RA. Our examination of clinical tissue samples and analysis of data sourced from the Gene Expression Omnibus dataset unveiled elevated expression levels of M1 macrophage markers in human RA synovial tissue samples compared to normal tissue, with no such distinction observed for M2 markers. Furthermore, immunofluorescence data depicted increased expression levels of NGF and M1 macrophages in RA mice in contrast to normal mice. It appears that NGF stimulation facilitates macrophage polarization from the M0 to the M1 phenotype. It also appears that NGF promotes ICAM-1 production in human RA synovial fibroblasts, which enhances monocyte adhesion through the TrkA, MEK/ERK, and AP-1 signaling cascades. Our findings indicate NGF/TrkA axis as a novel target for the treatment of RA.


Asunto(s)
Artritis Reumatoide , Molécula 1 de Adhesión Intercelular , Monocitos , Factor de Crecimiento Nervioso , Animales , Humanos , Ratones , Artritis Reumatoide/metabolismo , Molécula 1 de Adhesión Intercelular/metabolismo , Macrófagos/metabolismo , Monocitos/metabolismo , Factor de Crecimiento Nervioso/metabolismo
9.
Aging (Albany NY) ; 16(2): 1829-1844, 2024 01 22.
Artículo en Inglés | MEDLINE | ID: mdl-38261743

RESUMEN

The concept of osteoarthritis (OA) as a low-grade inflammatory joint disorder has been widely accepted. Many inflammatory mediators are implicated in the pathogenesis of OA. Interleukin (IL)-18 is a pleiotropic cytokine with versatile cellular functions that are pathogenetically important in immune responses, as well as autoimmune, inflammatory, and infectious diseases. IL-17, a proinflammatory cytokine mainly secreted by Th17 cells, is upregulated in OA patients. However, the role of IL-17 in OA progression is unclear. The synovial tissues collected from healthy donors and OA patients were used to detect the expression level of IL-18 by IHC stain. The OA synovial fibroblasts (OASFs) were incubated with recombinant IL-17 and subjected to Western blot, qPCR, and ELISA to examine IL-18 expression level. The chemical inhibitors and siRNAs which targeted signal pathways were used to investigate signal pathways involved in IL-17-induced IL-18 expression. The microRNAs which participated IL-18 expression were surveyed with online databases miRWalk and miRDB, followed by validation with qPCR. This study revealed significantly higher levels of IL-18 expression in synovial tissue from OA patients compared with healthy controls, as well as increased IL-18 expression in OASFs from rats with severe OA. In vitro findings indicated that IL-17 dose-dependently promoted IL-18 production in OASFs. Molecular investigations revealed that the MEK/ERK/miR-4492 axis stimulated IL-18 production when OASFs were treated with IL-17. This study provides novel insights into the role of IL-17 in the pathogenesis of OA, which may help to inform OA treatment in the future.


Asunto(s)
MicroARNs , Osteoartritis , Humanos , Ratas , Animales , Interleucina-17/metabolismo , Interleucina-18/metabolismo , Osteoartritis/metabolismo , Citocinas/metabolismo , MicroARNs/genética , MicroARNs/metabolismo , Fibroblastos/metabolismo , Quinasas de Proteína Quinasa Activadas por Mitógenos/metabolismo
10.
Aging (Albany NY) ; 15(22): 13163-13175, 2023 11 21.
Artículo en Inglés | MEDLINE | ID: mdl-37993261

RESUMEN

Chondrosarcoma is a primary malignant bone tumor. Traditional therapy is not very effective, and it is prone to metastasis in the late stage. The tumor microenvironment (TME) plays a key role in the progression and metastasis of chondrosarcoma, and hypoxia is one of the key factors in the formation of TME. However, the detailed mechanism of how hypoxia affects tumor progression and metastasis in chondrosarcoma is still not fully understood. In this study, we focused on the mechanism of interaction between hypoxic chondrosarcoma cells (SW1353) and macrophages. Our results suggest that hypoxia enhances the release of exosomes from chondrosarcoma cells. These hypoxia-induced exosomes promoted macrophage polarization towards the M2 phenotype, characterized by the expression of CD163 and CD206, but not the M1 phenotype, characterized by CD86 expression. Further analysis revealed that M2 macrophages polarized by exosomes expressed arginase-1 and feedback to chondrosarcoma cells to promote migration. These results suggest that chondrosarcoma cells secrete more exosomes in a hypoxic microenvironment, and these hypoxia-derived exosomes induce the polarization of macrophages into an M2 phenotype, ultimately promoting the metastatic behavior of chondrosarcoma cells.


Asunto(s)
Exosomas , MicroARNs , Humanos , Exosomas/metabolismo , Macrófagos/metabolismo , Línea Celular Tumoral , Hipoxia/metabolismo , Fenotipo , Microambiente Tumoral/genética , MicroARNs/metabolismo
11.
Int J Biol Sci ; 19(16): 5174-5186, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37928274

RESUMEN

Chondrosarcoma is the second most common type of bone cancer. At present, the most effective clinical course of action is surgical resection. Cisplatin is the chemotherapeutic medication most widely used for the treatment of chondrosarcoma; however, its effectiveness is severely hampered by drug resistance. In the current study, we compared cisplatin-resistant chondrosarcoma SW1353 cells with their parental cells via RNA sequencing. Our analysis revealed that glutamine metabolism is highly activated in resistant cells but glucose metabolism is not. Amphiregulin (AR), a ligand of the epidermal growth factor receptor, enhances glutamine metabolism and supports cisplatin resistance in human chondrosarcoma by promoting NADPH production and inhibiting reactive oxygen species (ROS) accumulation. The MEK, ERK, and NrF2 signaling pathways were shown to regulate AR-mediated alanine-serine-cysteine transporter 2 (ASCT2; also called SLC1A5) and glutaminase (GLS) expression as well as glutamine metabolism in cisplatin-resistant chondrosarcoma. The knockdown of AR expression in cisplatin-resistant chondrosarcoma cells was shown to reduce the expression of SLC1A5 and GLS in vivo. These results indicate that AR and glutamine metabolism are worth pursuing as therapeutic targets in dealing with cisplatin-resistant human chondrosarcoma.


Asunto(s)
Neoplasias Óseas , Condrosarcoma , Humanos , Cisplatino/farmacología , Cisplatino/uso terapéutico , Anfirregulina/genética , Glutamina , Resistencia a Antineoplásicos/genética , Condrosarcoma/tratamiento farmacológico , Condrosarcoma/genética , Línea Celular Tumoral , Antígenos de Histocompatibilidad Menor , Sistema de Transporte de Aminoácidos ASC
12.
Front Bioeng Biotechnol ; 11: 1247112, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37731760

RESUMEN

Background: In magnetic resonance imaging (MRI), lumbar disc herniation (LDH) detection is challenging due to the various shapes, sizes, angles, and regions associated with bulges, protrusions, extrusions, and sequestrations. Lumbar abnormalities in MRI can be detected automatically by using deep learning methods. As deep learning models gain recognition, they may assist in diagnosing LDH with MRI images and provide initial interpretation in clinical settings. YOU ONLY LOOK ONCE (YOLO) model series are often used to train deep learning algorithms for real-time biomedical image detection and prediction. This study aims to confirm which YOLO models (YOLOv5, YOLOv6, and YOLOv7) perform well in detecting LDH in different regions of the lumbar intervertebral disc. Materials and methods: The methodology involves several steps, including converting DICOM images to JPEG, reviewing and selecting MRI slices for labeling and augmentation using ROBOFLOW, and constructing YOLOv5x, YOLOv6, and YOLOv7 models based on the dataset. The training dataset was combined with the radiologist's labeling and annotation, and then the deep learning models were trained using the training/validation dataset. Results: Our result showed that the 550-dataset with augmentation (AUG) or without augmentation (non-AUG) in YOLOv5x generates satisfactory training performance in LDH detection. The AUG dataset overall performance provides slightly higher accuracy than the non-AUG. YOLOv5x showed the highest performance with 89.30% mAP compared to YOLOv6, and YOLOv7. Also, YOLOv5x in non-AUG dataset showed the balance LDH region detections in L2-L3, L3-L4, L4-L5, and L5-S1 with above 90%. And this illustrates the competitiveness of using non-AUG dataset to detect LDH. Conclusion: Using YOLOv5x and the 550 augmented dataset, LDH can be detected with promising both in non-AUG and AUG dataset. By utilizing the most appropriate YOLO model, clinicians have a greater chance of diagnosing LDH early and preventing adverse effects for their patients.

13.
Int J Adv Manuf Technol ; 126(3-4): 1093-1107, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37073280

RESUMEN

Surface defects are a common issue that affects product quality in the industrial manufacturing process. Many companies put a lot of effort into developing automated inspection systems to handle this issue. In this work, we propose a novel deep learning-based surface defect inspection system called the forceful steel defect detector (FDD), especially for steel surface defect detection. Our model adopts the state-of-the-art cascade R-CNN as the baseline architecture and improves it with the deformable convolution and the deformable RoI pooling to adapt to the geometric shape of defects. Besides, our model adopts the guided anchoring region proposal to generate bounding boxes with higher accuracies. Moreover, to enrich the point of view of input images, we propose the random scaling and the ultimate scaling techniques in the training and inference process, respectively. The experimental studies on the Severstal steel dataset, NEU steel dataset, and DAGM dataset demonstrate that our proposed model effectively improved the detection accuracy in terms of the average recall (AR) and the mean average precision (mAP) compared to state-of-the-art defect detection methods. We expect our innovation to accelerate the automation of industrial manufacturing process by increasing the productivity and by sustaining high product qualities.

14.
J Pineal Res ; 75(1): e12872, 2023 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-37057370

RESUMEN

Chondrosarcoma has a high propensity to metastasize and responds poorly to chemotherapy and radiation treatment. The enzymatic activity of matrix metalloproteinases (MMPs) is very important in chondrosarcoma metastasis. Melatonin exhibits anticarcinogenic activity in many types of cancers by suppressing the expression of certain MMP family members, but this has not yet been clearly determined in chondrosarcoma. Our study demonstrates that MMP7 plays an essential role in chondrosarcoma cell proliferation, migration, and anoikis resistance. We also found that MMP7 is highly expressed in chondrosarcomas. Our in vitro and in vivo investigations show that melatonin strongly inhibits chondrosarcoma cell proliferation, migration, and anoikis resistance by directly suppressing MMP7 expression. Melatonin reduced MMP7 synthesis by promoting levels of miR-520f-3p expression, which were downregulated in human chondrosarcoma tissue samples. Pharmacological inhibition of miR-520f-3p markedly reversed the effects of melatonin upon chondrosarcoma proliferation and metastasis. Thus, our study suggests that melatonin has therapeutic potential for reducing the tumorigenesis and metastatic potential of chondrosarcoma via the miR-520f-3p/MMP7 axis.


Asunto(s)
Condrosarcoma , Melatonina , MicroARNs , Humanos , MicroARNs/genética , Línea Celular Tumoral , Melatonina/farmacología , Metaloproteinasa 7 de la Matriz/metabolismo , Proliferación Celular , Condrosarcoma/tratamiento farmacológico , Condrosarcoma/genética , Condrosarcoma/metabolismo , Movimiento Celular , Regulación Neoplásica de la Expresión Génica
15.
Orthopedics ; 46(3): 169-174, 2023 May.
Artículo en Inglés | MEDLINE | ID: mdl-37018623

RESUMEN

Previous studies have reported that large fracture fragment with displacement might cause nonunion of femoral shaft fractures. We therefore intended to delineate significant risk factors for developing a nonunion predisposed by a major fracture fragment. We analyzed 61 patients who were operated on using interlocking nails for femoral shaft fractures from 2009 to 2018. We classified patients with modified Radiographic Union Scale for Tibia fractures scores of less than 11 or needing reoperations by 1 year postoperatively as nonunion. We thereafter measured parameters of the displaced fracture fragment and fracture site to identify the significant difference between the union and non-union groups. We also applied the receiver operating characteristic curve to demonstrate a threshold value for the fragment width (FW) ratio. Among 61 patients with complete follow-up, no significant difference was found regarding length, displacement, and angulation of fragments between patients with and without union. Except for higher mean FW (P=.03) and the FW ratio (P=.01) in patients with nonunion, the logistic regression analysis demonstrated that FW ratio significantly affected union (P=.018; odds ratio, 0.21; 95% CI, 0.001-0.522). Although a fracture fragment greater than 4 cm with displacement greater than 2 cm was reported to significantly cause nonunions, our study showed that an FW ratio greater than 0.55 instead of fragment size or displacement was predictive for the occurrence of nonunion adjoining to the fracture site. Fixation of the third fracture fragment should not be ignored for preventing a nonunion. More attention should be paid to achieve a better fixation for a major fracture fragment with an FW ratio greater than 0.55 to avoid the development of non-union following the use of interlocking nail for femoral shaft fracture. [Orthopedics. 2023;46(3):169-174.].


Asunto(s)
Fracturas del Fémur , Fijación Intramedular de Fracturas , Fracturas no Consolidadas , Humanos , Resultado del Tratamiento , Clavos Ortopédicos/efectos adversos , Estudios Retrospectivos , Fracturas no Consolidadas/diagnóstico por imagen , Fracturas no Consolidadas/cirugía , Fracturas no Consolidadas/epidemiología , Curación de Fractura , Fracturas del Fémur/diagnóstico por imagen , Fracturas del Fémur/cirugía , Fracturas del Fémur/complicaciones , Fijación Intramedular de Fracturas/efectos adversos
16.
Int J Mol Sci ; 24(1)2023 Jan 03.
Artículo en Inglés | MEDLINE | ID: mdl-36614283

RESUMEN

Chondrosarcoma is the second most common type of bone cancer. Surgical resection is the best choice for clinical treatment. High-grade chondrosarcoma is destructive and is more possible to metastasis, which is difficult to remove using surgery. Doxorubicin (Dox) is the most commonly used chemotherapy drug in the clinical setting; however, drug resistance is a major obstacle to effective treatment. In the present study, we compared Dox-resistant SW1353 cells to their parental cells using RNA sequencing (RNA-Seq). We found that the apelin (APLN) pathway was highly activated in resistant cells. In addition, tissue array analysis also showed that APLN was higher in high-grade tissues compared to low-grade tissues. APLN is a member of the adipokine family, which is a novel secreted peptide with multifunctional and biological activities. Previously, studies have shown that inhibition of the APLN axis may have a therapeutic benefit in cancers. However, the role of APLN in chondrosarcoma is completely unclear, and no related studies have been reported. During in vitro experiments, APLN was also observed to be highly expressed and secreted in Dox-resistant cells. Once APLN was knocked down, it could effectively improve its sensitivity to Dox. We also explored possible upstream regulatory microRNAs (miRNAs) of APLN through bioinformatics tools and the results disclosed that miR-631 was the most likely regulator of APLN. Furthermore, the expression of miR-631 was lower in the resistant cells, but overexpression of miR-631 in the Dox-resistant cell lines significantly increased the Dox sensitivity. These results were also observed in another chondrosarcoma cell line, JJ012 cells. Taken together, these findings will provide rationale for the development of drug resistance biomarkers and therapeutic strategies for APLN pathway inhibitors to improve the survival of patients with chondrosarcoma.


Asunto(s)
Apelina , Neoplasias Óseas , Condrosarcoma , Doxorrubicina , Resistencia a Antineoplásicos , MicroARNs , Humanos , Apelina/genética , Apelina/metabolismo , Neoplasias Óseas/tratamiento farmacológico , Neoplasias Óseas/genética , Neoplasias Óseas/metabolismo , Condrosarcoma/tratamiento farmacológico , Condrosarcoma/genética , Condrosarcoma/metabolismo , Doxorrubicina/farmacología , Doxorrubicina/uso terapéutico , MicroARNs/genética , MicroARNs/uso terapéutico
17.
Sensors (Basel) ; 23(2)2023 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-36679785

RESUMEN

Anomalies are a set of samples that do not follow the normal behavior of the majority of data. In an industrial dataset, anomalies appear in a very small number of samples. Currently, deep learning-based models have achieved important advances in image anomaly detection. However, with general models, real-world application data consisting of non-ideal images, also known as poison images, become a challenge. When the work environment is not conducive to consistently acquiring a good or ideal sample, an additional adaptive learning model is needed. In this work, we design a potential methodology to tackle poison or non-ideal images that commonly appear in industrial production lines by enhancing the existing training data. We propose Hierarchical Image Transformation and Multi-level Features (HIT-MiLF) modules for an anomaly detection network to adapt to perturbances from novelties in testing images. This approach provides a hierarchical process for image transformation during pre-processing and explores the most efficient layer of extracted features from a CNN backbone. The model generates new transformations of training samples that simulate the non-ideal condition and learn the normality in high-dimensional features before applying a Gaussian mixture model to detect the anomalies from new data that it has never seen before. Our experimental results show that hierarchical transformation and multi-level feature exploration improve the baseline performance on industrial metal datasets.


Asunto(s)
Procesamiento de Imagen Asistido por Computador , Procesamiento de Imagen Asistido por Computador/métodos , Distribución Normal
18.
IEEE Trans Cybern ; 53(4): 2494-2505, 2023 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-34793316

RESUMEN

In recent years, ensemble methods have shown sterling performance and gained popularity in visual tasks. However, the performance of an ensemble is limited by the paucity of diversity among the models. Thus, to enrich the diversity of the ensemble, we present the distillation approach-learning from experts (LFEs). Such method involves a novel knowledge distillation (KD) method that we present, specific expert learning (SEL), which can reduce class selectivity and improve the performance on specific weaker classes and overall accuracy. Through SEL, models can acquire different knowledge from distinct networks with various areas of expertise, and a highly diverse ensemble can be obtained afterward. Our experimental results demonstrate that, on CIFAR-10, the accuracy of the ResNet-32 increases 0.91% with SEL, and that the ensemble trained by SEL increases accuracy by 1.13%. Compared to state-of-the-art approaches, for example, DML only improves accuracy by 0.3% and 1.02% on single ResNet-32 and the ensemble, respectively. Furthermore, our proposed architecture also can be applied to ensemble distillation (ED), which applies KD on the ensemble model. In conclusion, our experimental results show that our proposed SEL not only improves the accuracy of a single classifier but also boosts the diversity of the ensemble model.

19.
J Clin Pharmacol ; 63(3): 288-297, 2023 03.
Artículo en Inglés | MEDLINE | ID: mdl-36399336

RESUMEN

This systematic review was performed to determine the population that benefited from prophylactic ivermectin. Seven databases of health-related studies were searched for eligible trials without language restrictions. Randomized controlled trials (RCTs) and cohort studies investigating ivermectin for coronavirus disease 2019 (COVID-19) prevention were included. Data were pooled using a random-effects model, and subgroups were analyzed by study type and the pre- or postexposure population. The certainty of the evidence was determined by the Grading of Recommendations Assessment, Development, and Evaluation approach. Furthermore, 4 RCTs and 4 cohort studies with a moderate to high risk of bias were included in the analysis. The prophylactic use of ivermectin significantly decreased the overall incidence of COVID-19 (odds ratio [OR], 0.26; 95% confidence interval [CI], 0.16-0.44). Nevertheless, the positive result was not supported by the RCT. Ivermectin was associated with a lower risk of COVID-19 (OR, 0.22; 95% CI, 0.12-0.40) in the preexposure population, whereas no protective effect was observed in the postexposure population (OR, 0.39; 95% CI, 0.09-1.67). In summary, prophylactic ivermectin did not prevent COVID-19 in the postexposure population. Although the protective effect of ivermectin was shown in the overall and preexposure populations, the results were unreliable owing to poor-quality evidence.


Asunto(s)
COVID-19 , Humanos , COVID-19/prevención & control , Ivermectina/uso terapéutico , Sesgo , Proyectos de Investigación , Oportunidad Relativa
20.
Cells ; 11(21)2022 11 02.
Artículo en Inglés | MEDLINE | ID: mdl-36359873

RESUMEN

New treatments for chondrosarcoma are extremely important. Chondrosarcoma is a primary malignant bone tumor with a very unfavorable prognosis. High-grade chondrosarcoma has a high potential to metastasize to any organ in the body. Platelet-derived growth factor (PDGF) is a potent angiogenic factor that promotes tumor angiogenesis and metastasis. The adipocytokine visfatin promotes metastatic potential of chondrosarcoma; however, the role of visfatin in angiogenesis in human chondrosarcoma is unclear. We report that the levels of PDGF-C expression were positively correlated with tumor stages, significantly higher than the levels of expression in normal cartilage. Visfatin increased PDGF-C expression and endothelial progenitor cell (EPC) angiogenesis through the PI3K/Akt/mTOR signaling pathway, and dose-dependently down-regulated the synthesis of miR-1264, which targets the 3'-UTR of PDGF-C. Additionally, we discovered inhibition of visfatin or PDGF-C in chondrosarcoma tumors significantly reduced tumor angiogenesis and size. Our results indicate that visfatin inhibits miR-1264 production through the PI3K/Akt/mTOR signaling cascade, and thereby promotes PDGF-C expression and chondrosarcoma angiogenesis. Visfatin may be worth targeting in the treatment of chondrosarcoma angiogenesis.


Asunto(s)
Neoplasias Óseas , Condrosarcoma , Células Progenitoras Endoteliales , MicroARNs , Humanos , Células Progenitoras Endoteliales/metabolismo , Nicotinamida Fosforribosiltransferasa/genética , Nicotinamida Fosforribosiltransferasa/metabolismo , Fosfatidilinositol 3-Quinasas/metabolismo , Proteínas Proto-Oncogénicas c-akt/metabolismo , Factor A de Crecimiento Endotelial Vascular/metabolismo , Condrosarcoma/metabolismo , Neovascularización Patológica/metabolismo , Factor de Crecimiento Derivado de Plaquetas/metabolismo , Serina-Treonina Quinasas TOR/metabolismo , Neoplasias Óseas/metabolismo , MicroARNs/genética , MicroARNs/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...